SCHEMBL1069105

SCHEMBL1069105

CCOC(=O)C=C(C)Oc1cccc(F)c1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 5/20 0.40
NLRP3 Q96P20 1/20 0.38
KDM4E B2RXH2 5/20 0.36
CYP1A2 P05177 3/20 0.36
ALDH1A1 P00352 3/20 0.36
RAB9A P51151 3/20 0.36
CYP2C19 P33261 2/20 0.36
NPC1 O15118 2/20 0.36
MAPT P10636 5/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
NPSR1 Q6W5P4 3/20 0.36
POLB P06746 1/20 0.36
PKM P14618 1/20 0.36
GALK1 P51570 1/20 0.36
CCR6 P51684 1/20 0.36
BLM P54132 1/20 0.36
MCL1 Q07820 1/20 0.36
HKDC1 Q2TB90 1/20 0.36
MEN1 O00255 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1069104 1.00 SMN1; SMN2 (0.40) SMN1; SMN2KMT2ANLRP3KDM4ECYP1A2
SCHEMBL1069102 1.00 SMN1; SMN2 (0.40) SMN1; SMN2KMT2ANLRP3KDM4ECYP1A2
SCHEMBL1063774 0.90 CYP1A2 (0.37) SMN1; SMN2KMT2ANLRP3KDM4ECYP1A2
SCHEMBL1063772 0.90 CYP1A2 (0.37) SMN1; SMN2KMT2ANLRP3KDM4ECYP1A2
SCHEMBL1063770 0.90 CYP1A2 (0.37) SMN1; SMN2KMT2ANLRP3KDM4ECYP1A2
SCHEMBL1065377 0.89 KMT2A (0.41) SMN1; SMN2KMT2AKDM4ECYP1A2ALDH1A1
SCHEMBL1067503 0.89 NPSR1 (0.38) SMN1; SMN2KMT2AKDM4ECYP1A2ALDH1A1
SCHEMBL1065376 0.89 KMT2A (0.41) SMN1; SMN2KMT2AKDM4ECYP1A2ALDH1A1
SCHEMBL1067485 0.88 MAPT (0.41) SMN1; SMN2KMT2AKDM4ECYP1A2RAB9A
SCHEMBL1067483 0.88 MAPT (0.41) SMN1; SMN2KMT2AKDM4ECYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 SMN1; SMN2 2392/4885KMT2A 2072/4885NLRP3 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.